Literature DB >> 23524243

Regulation of mevalonate metabolism in cancer and immune cells.

Martin Thurnher1, Georg Gruenbacher, Oliver Nussbaumer.   

Abstract

The mevalonate pathway is a highly conserved metabolic cascade and provides isoprenoid building blocks for the biosynthesis of vital cellular products such as cholesterol or prenyl pyrophosphates that serve as substrates for the posttranslational prenylation of numerous proteins. The pathway, which is frequently hyperactive in cancer cells, is considered an important target in cancer therapy, since prenylated members of the Ras superfamily are crucially involved in the control of proliferation, survival, invasion and metastasis of tumour cells. Upstream accumulation and downstream depletion of mevalonate pathway intermediates as induced for instance by aminobisphosphonates translate into different effects in cancer and immune cells. Thus, mevalonate pathway regulation can affect tumour biology either directly or exhibit indirect antitumour effects through stimulating cancer immune surveillance. The present review summarizes major effects of pharmacologic mevalonate pathway regulation in cancer and immune cells that may collaboratively contribute to the efficacy of cancer therapy.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23524243     DOI: 10.1016/j.bbalip.2013.03.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  34 in total

Review 1.  Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway.

Authors:  Annalisa Marcuzzi; Elisa Piscianz; Claudia Loganes; Liza Vecchi Brumatti; Alessandra Knowles; Sabrine Bilel; Alberto Tommasini; Roberta Bortul; Marina Zweyer
Journal:  Int J Mol Sci       Date:  2015-12-30       Impact factor: 5.923

2.  γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?

Authors:  Jaydeep Bhat; Dieter Kabelitz
Journal:  Oncoimmunology       Date:  2015-04-28       Impact factor: 8.110

Review 3.  Statins and breast cancer prognosis: evidence and opportunities.

Authors:  Thomas P Ahern; Timothy L Lash; Per Damkier; Peer M Christiansen; Deirdre P Cronin-Fenton
Journal:  Lancet Oncol       Date:  2014-09       Impact factor: 41.316

4.  Stress-related and homeostatic cytokines regulate Vγ9Vδ2 T-cell surveillance of mevalonate metabolism.

Authors:  Georg Gruenbacher; Oliver Nussbaumer; Hubert Gander; Bernhard Steiner; Nicolai Leonhartsberger; Martin Thurnher
Journal:  Oncoimmunology       Date:  2014-11-14       Impact factor: 8.110

5.  In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors.

Authors:  Jacqueline E Reilly; Xiang Zhou; Huaxiang Tong; Craig H Kuder; David F Wiemer; Raymond J Hohl
Journal:  Biochem Pharmacol       Date:  2015-05-04       Impact factor: 5.858

6.  Original Research: Atorvastatin prevents rat cardiomyocyte hypertrophy induced by parathyroid hormone 1-34 associated with the Ras-ERK signaling.

Authors:  Xiaogang Liu; Chunbo Zou; Chengyuan Yu; Rujuan Xie; Manshu Sui; Suhong Mu; Li Li; Shilei Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

7.  Cholesterol metabolism and Rett syndrome pathogenesis.

Authors:  Gabor Nagy; Susan L Ackerman
Journal:  Nat Genet       Date:  2013-09       Impact factor: 38.330

8.  Zoledronic acid causes γδ T cells to target monocytes and down-modulate inflammatory homing.

Authors:  Daniel W Fowler; John Copier; Angus G Dalgleish; Mark D Bodman-Smith
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

Review 9.  The interplay between mutant p53 and the mevalonate pathway.

Authors:  Alejandro Parrales; Elizabeth Thoenen; Tomoo Iwakuma
Journal:  Cell Death Differ       Date:  2017-12-13       Impact factor: 15.828

Review 10.  The cholesterol pathway: impact on immunity and cancer.

Authors:  Ryan J King; Pankaj K Singh; Kamiya Mehla
Journal:  Trends Immunol       Date:  2022-01       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.